Trial Profile

Study of the Effect of Atorvastatin for Reducing "Inflaming" (Aging-related Complication) in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary) ; Raltegravir (Primary) ; Atazanavir; Darunavir; Fosamprenavir; Indinavir; Lopinavir; Ritonavir; Saquinavir; Tipranavir
Indications HIV infections
Focus Biomarker; Pharmacodynamics
Acronyms RALATOR

24 Jul 2018 Status changed from active, no longer recruiting to completed.
04 Apr 2018 Planned End Date changed from 31 Aug 2018 to 21 Jun 2018.
04 Apr 2018 Planned primary completion date changed from 31 Aug 2018 to 21 Jun 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com